Camillo Porta,Carlo Ganini,Mimma Rizzo et al.
Camillo Porta et al.
Re: Jurczok N, Dernbach G, Ebner B, et al. Multiregional immune profiling reveals prognostic patterns in bladder cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2025.12.006 [0.03%]
关于Jurczok N, Dernbach G, Ebner B等人的研究“多区域免疫谱分析揭示膀胱癌的预后模式”. Eur Urol Oncol. 在线发表中. http://dx.doi.org/10.1016/j.euo.2025.12.006
Kiyo Yoshida,Souichi Oka,Yoshiyasu Takefuji
Kiyo Yoshida
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials [0.03%]
一项卡巴他赛治疗转移性去势抵抗性前列腺癌的综合预后评分：来自CABASTY事后分析并经两项国际前瞻性Ⅲ期临床试验验证
Charles Vauchier,Constance Thibault,Maud Velev et al.
Charles Vauchier et al.
Background and objective: Optimal therapy after docetaxel and an androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer (mCRPC) remains debated. We aimed to build and validate the ca...
Deep Systemic Response in Muscle-invasive Bladder Cancer: Is Radical Cystectomy Still Necessary? [0.03%]
肌侵袭性膀胱癌深度系统反应：根治性膀胱切除术还有必要吗？
Xu-Shan Sun,Jihane Boustani,Roger Sun
Xu-Shan Sun
Re: Michael Baboudjian, Alessandro Uleri, Julien Anract, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.006 [0.03%]
前列腺癌的靶区、病灶周围和远隔活检 Michaël Baboudjian等
Alexander Light,Hashim U Ahmed,Taimur T Shah
Alexander Light
Re: Sebastian C. Schmid, Matthias Jahnen, Kilian Schiller, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Oncol. In press. http://doi.org/10.1016/j.euo.2026.02.019 [0.03%]
根治性膀胱切除术前放射治疗联合免疫治疗治疗局部晚期膀胱癌的前瞻性、单臂、多中心Ⅱ期临床研究（RACE-IT）
Neeraj Singh,Monika Srivastav
Neeraj Singh
Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer [0.03%]
ROGUE-1登记处的设计与原理：一项针对原发T1肌层外膀胱癌的多中心前瞻性登记研究
David D&#x;Andrea,Francesco Soria,Morgan Rouprêt et al.
David D&#x;Andrea et al.
Background and objective: Patients with T1 nonmuscle-invasive bladder cancer (NMIBC) face substantial risks of recurrence and progression to muscle-invasive disease. However, current risk stratification tools rely on retr...
Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008 [0.03%]
无前列腺特异性抗原进展的转移性激素敏感性前列腺癌的放射学进展：ENZAMET试验（ANZUP 1304）的回顾性分析
Phuoc T Tran,Matthew P Deek,Philip Sutera
Phuoc T Tran
Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients [0.03%]
大体积局灶性前列腺癌立体定向放疗(SHARP)联盟的长期随访结果：440例患者分析
Luca F Valle,Tahmineh Romero-Kalbasi,Tommy Jiang et al.
Luca F Valle et al.
Background and objective: Most patients with high-risk localized prostate cancer (HRLPC) do not undergo stereotactic body radiotherapy (SBRT) in part because of the limited evidence of long-term outcomes. We report long-t...
Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy [0.03%]
联合基因组前列腺评分与术前和术后前列腺癌风险评估评分预测根治性前列腺切除术后生化复发
Yu Ozawa,Marcio Covas Moschovas,Marco Sandri et al.
Yu Ozawa et al.
Background and objective: Cancer of the Prostate Risk Assessment (CAPRA) score and its postsurgical variant (CAPRA-S) predict biochemical recurrence (BCR) after radical prostatectomy (RP) but do not capture tumor biology....